iScience Interventional, a private device and imaging company in Menlo Park, California, have announced the execution of a clinical and commercial supply agreement with Johnson… Read More »iScience Interventional announces micro-catheter supply deal with J&J for cell therapy AMD trial
Roche (SIX:ROG; OTCQX:RHHBY) has reported that 3Q11 US sales of Lucentis (ranibizumab) grew by 17% to CHF359M/US$392M. The increase in sales occurs against the backdrop… Read More »Roche sees Lucentis sales increase and announces data from Phase III HARBOR trial
UK company Optos, plc (LSE: OPTS) has announced its next generation imaging device, branded “Daytona”, at the Boston meeting of the American Academy of Optometry.… Read More »Optos, plc unveils next generation desktop imaging device at American Academy of Optometry meeting
VisionCare Ophthalmic Technologies, Inc., a specialty medical device company based in Saratoga California, have announced that the Centres for Medicare and Medicaid Services (CMS), a… Read More »VisionCare’s implantable telescope secures reimbursement
A new UK-based ophthalmology company – KalVista Pharmaceuticals – has announced the completion of an £8 million Series A funding round led by Novo A/S… Read More »A new ophthalmic company – KalVista Pharmaceuticals – raises £8M to fund DME therapies
iCo Therapeutics (TSX-V: ICO, Vancouver, Canada) has announced the execution of a licensing deal with Immune Pharmaceuticals (Ness-Ziona, Israel) for Bertilimumab (iCo-008) for systemic uses.… Read More »iCo Therapeutics enters license deal with Immune Pharmaceuticals
Pfizer, Inc (NYSE: PFE), New York, has notified the European Medicines Agency (EMA) of its decision to withdraw an application to extend the therapeutic indication… Read More »Pfizer withdraws application for an extension of the indication for Macugen
Regeneron Pharmaceuticals (NASDAQ:REGN), Tarrytown, New York, will undergo an FDA priority review of its VEGF Trap Eye (recently renamed “Eylea aflibercept”) on August 20th, the… Read More »Regeneron Pharmaceutical’s pricing strategy may be key to success
In a collaboration with the University of Birmingham, Quark Pharmaceuticals, a Californian based biotech company with research facilities at the Weismann Science Park in Israel,… Read More »Quark Pharmaceuticals Inc. and the University of Birmingham publishes data on anti-apoptotic result
Regeneron Pharmaceuticals & Bayer Healthcare have announced the submission of a marketing authorisation application (MAA) for VEGF Trap Eye for the treatment of neovascular age… Read More »Regeneron & Bayer file marketing authorisation application for VEGF Trap Eye